Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).

Abstract:

INTRODUCTION:The cyclic nucleotides cAMP and cGMP are ubiquitous intracellular second messengers regulating a large variety of biological processes. The intracellular concentration of these biologically relevant molecules is modulated by the activity of phosphodiesterases (PDEs), a class of enzymes that is grouped in 11 families. The expression of PDEs is tissue- and cell-specific allowing spatiotemporal integration of multiple signaling cascades. PDE2A is a dual substrate enzyme and is expressed in both the periphery and in the central nervous system, however its expression is highest in the brain, where it is mainly localized in the cortex, hippocampus, and striatum. This suggests that this enzyme may regulate intraneuronal cGMP and cAMP levels in brain areas involved in emotion, perception, concentration, learning and memory. AREAS COVERED:This review covers the patent applications published between January 2010 and February 2016 on phosphodiesterase 2A inhibitors. EXPERT OPINION:Recent publications in the literature and in filed patent applications demonstrate the interest of pharmaceutical companies for PDE2A. This has increased the insights of its possible therapeutic role but the few clinical trials were terminated. Based on the ongoing interest in the field it is likely that new clinical trials can be expected and will unravel the therapeutic potential of PDE2A inhibition.

journal_name

Expert Opin Ther Pat

authors

Trabanco AA,Buijnsters P,Rombouts FJ

doi

10.1080/13543776.2016.1203902

subject

Has Abstract

pub_date

2016-08-01 00:00:00

pages

933-46

issue

8

eissn

1354-3776

issn

1744-7674

journal_volume

26

pub_type

杂志文章,评审
  • Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).

    abstract:INTRODUCTION:The NF-E2-related factor-2 (Nrf2) is a critical transcription factor that regulates the expression of many phase II and antioxidant genes to maintain the homeostasis. It has many biological functions and plays a central role in the cellular defensive machinery. The abnormal regulation of Nrf2 is closely as...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2017.1325464

    authors: Sun H,Zhu J,Lin H,Gu K,Feng F

    更新日期:2017-07-01 00:00:00

  • ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents.

    abstract:INTRODUCTION:The bacterial topoisomerases DNA gyrase and topoisomerase IV are validated targets for development of novel antibacterial agents. Fluoroquinolones inhibit the catalytic GyrA and/or ParC(GrlA) subunit and have been commonly used, although these have toxicity liabilities that restrict their use. The ATPase G...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2019.1575362

    authors: Durcik M,Tomašič T,Zidar N,Zega A,Kikelj D,Mašič LP,Ilaš J

    更新日期:2019-03-01 00:00:00

  • GPR119 agonists for the treatment of type 2 diabetes.

    abstract:BACKGROUND:Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin, or when the body cannot effectively use the insulin it produces. Hyperglycemia, or raised blood sugar, is a common effect of uncontrolled diabetes and over time leads to serious damage to many of the body's systems, ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543770903153878

    authors: Jones RM,Leonard JN,Buzard DJ,Lehmann J

    更新日期:2009-10-01 00:00:00

  • Phosphoinositide 3-kinase α inhibitors: a patent review.

    abstract:INTRODUCTION:The alpha isoform of the class 1A family of phosphatidylinositol 3-kinases (PI3Kα) has been extensively studied and exploited as a target for cancer drugs. A large number of compounds, from a wide variety of structural scaffolds, are in development. There is an ongoing debate about the desirability for sel...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2013.779673

    authors: Denny WA

    更新日期:2013-07-01 00:00:00

  • T-type calcium channels inhibitors: a patent review.

    abstract:IMPORTANCE OF THE FIELD:T-type calcium channels are transmembrane proteins that regulate calcium entry in the cell in a voltage-dependent manner. Intracellular calcium levels are the key to many physiological processes, ranging from neuron firing to cardiac pacemaking. Inhibition of T-type calcium channels is heralded ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.536532

    authors: Giordanetto F,Knerr L,Wållberg A

    更新日期:2011-01-01 00:00:00

  • Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010).

    abstract:INTRODUCTION:Non-nucleoside reverse transcriptase inhibitors (NNRTIs) form the backbone of antiretroviral treatment for many HIV-infected individuals. The unique antiviral activity, high specificity and low toxicity associated with this class of agents make them a frequent choice for first-line therapy. However, the ef...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.568481

    authors: Zhan P,Liu X

    更新日期:2011-05-01 00:00:00

  • Medicine patent pool--pharma philanthropy or PR?

    abstract::Merck recently signed an agreement with The Medicines Patent Pool (MPP) to license intellectual property relating to pediatric formulations of its integrase HIV drug, raltegravir (Ral) (the 'Agreement'). The Agreement is alleged to clear the way for cheaper formulations for use in developing and some middle income cou...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 社论

    doi:10.1517/13543776.2015.1075004

    authors: De Luca C

    更新日期:2015-01-01 00:00:00

  • New patented histone deacetylase inhibitors.

    abstract:IMPORTANCE OF THE FIELD:Following FDA approval of vorinostat in 2006, several novel HDAC inhibitors (HDACis) have entered clinical trials, and there are numerous published patent applications claiming novel HDACis which were optimized as potential drug candidates, designed for regional or systemic release, and created ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543770903393789

    authors: Wang H,Dymock BW

    更新日期:2009-12-01 00:00:00

  • Novel thyrotropin-releasing hormone analogs: a patent review.

    abstract:INTRODUCTION:The potential therapeutic applications of thyrotropin-releasing hormone (TRH) have attracted attention, based on its broad-spectrum neuropharmacological action rather than its endocrine properties. These central nervous system (CNS)-mediated effects provide the rationale for use of TRH and its analogs in t...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.623127

    authors: Khomane KS,Meena CL,Jain R,Bansal AK

    更新日期:2011-11-01 00:00:00

  • Bitopic muscarinic agonists and antagonists and uses thereof: a patent evaluation of US20160136145A1.

    abstract:INTRODUCTION:Bitopic M ligands, that is, ligands that interact both with the ortho- and allosteric binding sites of the M receptor subtypes, hold great potential as novel selective for muscarinic acetylcholine (M) ligands for several therapeutic applications. Areas covered: The patent application describes a set of com...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2017.1272577

    authors: Holzgrabe U,Decker M

    更新日期:2017-02-01 00:00:00

  • Lessons from black pepper: piperine and derivatives thereof.

    abstract:INTRODUCTION:Piperine is a simple and pungent alkaloid found in the seeds of black pepper (Piper nigrum). Following its isolation and full characterization, the biological properties of piperine have been extensively studied, and piperine-like derivatives have shown an interesting range of pharmacological activities. I...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2016.1118057

    authors: Chavarria D,Silva T,Magalhães e Silva D,Remião F,Borges F

    更新日期:2016-01-01 00:00:00

  • Nuclear factor-kappa B inhibitors; a patent review (2006-2010).

    abstract:INTRODUCTION:Nuclear factor (NF)-κB, as transcription factor, is linked to the expression of various genes and plays an essential role in immune and inflammatory responses. Abnormal NF-κB signaling results in human diseases, such as immune disorders, inflammation and various cancers. Therefore, regulation of NF-κB may ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.638285

    authors: Kwak JH,Jung JK,Lee H

    更新日期:2011-12-01 00:00:00

  • FAK inhibitors in Cancer, a patent review.

    abstract:INTRODUCTION:Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that localizes at sites of cell adhesion to the extracellular matrix (ECM) and mediates signalling events downstream of integrin engagement of the ECM. FAK is known to regulate cell survival, proliferation and migration. AREAS COVERED:FAK expre...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1414183

    authors: Lv PC,Jiang AQ,Zhang WM,Zhu HL

    更新日期:2018-02-01 00:00:00

  • Human neural progenitor and stem cells: US20080107633A1.

    abstract:BACKGROUND:The application is in the field of neural stem cells (NSCs) and cellular therapy. OBJECTIVE:It aims at establishing conditions for the isolation and propagation of neural progenitor and stem cells from human fetal tissue, with high rate of growth and high yields of differentiation into the neuronal, astrogl...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543770802688909

    authors: Taupin P

    更新日期:2009-03-01 00:00:00

  • The therapeutic potential of PROTACs.

    abstract:INTRODUCTION:PROTACs represent a novel class of heterobifunctional molecules that simultaneously bind to a target protein and to an E3 ligase complex, resulting in the transfer of ubiquitin and initiating a process ultimately causing the proteasomal degradation of the target protein. This mechanism of action imbues PRO...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2021.1840553

    authors: Benowitz AB,Jones KL,Harling JD

    更新日期:2021-01-01 00:00:00

  • Novel epigallocatechin gallate analogs as potential anticancer agents: a patent review (2009 - present).

    abstract:INTRODUCTION:Over the past three years numerous patents and patent applications have been published relating to scientific advances in the use of the green tea polyphenol epigallocatechin gallate (EGCG) (the most abundant, and bioactive compound in green tea) and its analogs as anticancer agents. EGCG affects multiple ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2013.743993

    authors: Landis-Piwowar K,Chen D,Foldes R,Chan TH,Dou QP

    更新日期:2013-02-01 00:00:00

  • Solid lipid nanoparticles: a review on recent perspectives and patents.

    abstract::Introduction: Solid lipid nanoparticles (SLNs) are solid core lipid nanocarriers, which can hold both hydrophilic and hydrophobic drugs. They can be made up of biocompatible ingredients and therefore are one of the preferred choices for drug delivery. Surface modifications of SLNs may further provide unique features t...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2020.1720649

    authors: Paliwal R,Paliwal SR,Kenwat R,Kurmi BD,Sahu MK

    更新日期:2020-03-01 00:00:00

  • Inhibitors of the renal outer medullary potassium channel: a patent review.

    abstract:INTRODUCTION:Hypertension represents a substantial cardiovascular risk factor. Among anti-hypertensive drugs, diuretics play an important role. Nevertheless, they present adverse effects such as hypokalemia or hyperkalemia. In this panorama, inhibitors of the renal outer medullary potassium (ROMK) channels are emerging...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2015.1050792

    authors: Martelli A,Testai L,Breschi MC,Calderone V

    更新日期:2015-01-01 00:00:00

  • Transport molecules using reverse sequence HIV-Tat polypeptides: not just any old Tat? (WO200808225).

    abstract:BACKGROUND:Many polycationic cell penetrating peptides (CPPs), alternatively named protein transduction domains, have been used for the efficient intracellular delivery of biologically active agents. Patent WO2008/082885 relates to the properties and proposed biomedical applications of a CPP and putative-related sequen...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/17530050902824829

    authors: Howl J,Jones S

    更新日期:2009-09-01 00:00:00

  • A patent review on the development of human cytochrome P450 inhibitors.

    abstract:INTRODUCTION:CYP, a ubiquitous superfamily of enzymes expressed in major organs in humans, plays a key role in biosynthesis of steroids and metabolism of xenobiotics. Inhibitors of these vital enzymes provide, as tools, the opportunity to gain an insight to their role in a myriad of bioactivity and to intervene as ther...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.899583

    authors: Francis S,Delgoda R

    更新日期:2014-06-01 00:00:00

  • Small molecule c-Met kinase inhibitors: a review of recent patents.

    abstract:IMPORTANCE OF THE FIELD:c-Met kinase is the receptor for hepatocyte growth factor. Primarily expressed on epithelial and mesenchymal cells its normal function is associated with wound healing, liver regeneration and embryo development. However, dysregulation of c-Met through overexpression, gene amplification, mutation...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543770903514137

    authors: Porter J

    更新日期:2010-02-01 00:00:00

  • Retinoid X receptor ligands: a patent review (2007 - 2013).

    abstract:INTRODUCTION:Retinoid X receptors (RXRs) are nuclear receptors that act as ligand-dependent transcription factors. RXRs function as homodimers or as heterodimers with other nuclear receptors, such as retinoic acid receptors, PPARs, liver X receptors, farnesoid X receptor, vitamin D receptor or thyroid hormone receptors...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.880692

    authors: Yamada S,Kakuta H

    更新日期:2014-04-01 00:00:00

  • Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).

    abstract:INTRODUCTION:Since exendin-4 (exenatide) was approved for diabetes therapy in 2005, several exendin analogs have been developed for the treatment of type 2 diabetes mellitus. As exenatide is a relatively short-acting injectable agent, major approaches have focused on developing long-acting exendin analogs to improve pa...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2016.1192130

    authors: Park EJ,Lim SM,Lee KC,Na DH

    更新日期:2016-07-01 00:00:00

  • Lessons from glucokinase activators: the problem of declining efficacy.

    abstract::The concept of activation of glucokinase (encoded by the Gck gene) as a potential therapy for type 2 diabetes has been explored by several pharmaceutical companies. Small-molecule Gck activators (GKAs) were found to be effective at increasing glucose disposal by hepatocytes and lowering blood glucose in animal models ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.965680

    authors: Agius L

    更新日期:2014-11-01 00:00:00

  • Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections.

    abstract:INTRODUCTION:Amino acid depletion in the blood serum is currently being exploited and explored for therapies in tumors or viral infections that are auxotrophic for a certain amino acid or have a metabolic defect and cannot produce it. The success of these treatments is because normal cells remain unaltered since they a...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2017.1254194

    authors: Fernandes HS,Silva Teixeira CS,Fernandes PA,Ramos MJ,Cerqueira NM

    更新日期:2017-03-01 00:00:00

  • Transglutaminase inhibitors: a patent review.

    abstract:INTRODUCTION:Transglutaminases (TGases) are a class of enzymes that play multifunctional roles. Their protein-crosslinking activity has been linked to fibrosis and Huntington's disease, their glutamine deamidation activity has been related to celiac disease and their GTP-binding activity has been implicated in cancer. ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2016.1115836

    authors: Keillor JW,Apperley KY

    更新日期:2016-01-01 00:00:00

  • Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).

    abstract:INTRODUCTION:The non-receptor tyrosine kinase, inducible tyrosine kinase (Itk), plays an important role in thymus(T)-cell signalling and the production of pro-inflammatory cytokines. Itk, and the other Tec family members, Rlk and Tec, are viewed as attractive drug targets for new agents for the treatment of autoimmune ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.936381

    authors: Norman P

    更新日期:2014-09-01 00:00:00

  • Novel pharmacological modulators of autophagy: an updated patent review (2012-2015).

    abstract:INTRODUCTION:Autophagy is a lysosome-dependent degradation pathway that maintains cellular homeostasis in response to a variety of cellular stresses. Accumulating reports based on animal models have indicated the importance of this catabolic program in many human pathophysiological conditions, including diabetes, neuro...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2016.1217996

    authors: Ha J,Kim J

    更新日期:2016-11-01 00:00:00

  • TBK1 inhibitors: a review of patent literature (2011 - 2014).

    abstract:INTRODUCTION:TANK-binding kinase 1 (TBK1) is a noncanonical IκB kinase family member that regulates the innate immune response. Misregulation of TBK1 activity can promote inflammatory disorders and oncogenesis; therefore, TBK1 inhibitors are considered a promising therapy for inflammation and cancer. AREAS COVERED:In ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2015.1081168

    authors: Yu T,Yang Y,Yin DQ,Hong S,Son YJ,Kim JH,Cho JY

    更新日期:2015-01-01 00:00:00

  • Long-acting muscarinic M3 receptor antagonists.

    abstract::A series of 10 closely related patent applications define Theravance's approach to the development of long-acting M(3) selective antagonists for the treatment of chronic obstructive pulmonary disease. The applications illustrate a modular approach to the design of such agents, comprising a muscarinic pharmacophore att...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.16.9.1321

    authors: Norman P

    更新日期:2006-09-01 00:00:00